Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(3.11)
# 2,677
Out of 5,182 analysts
121
Total ratings
45.37%
Success rate
1.25%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Maintains: Buy | $14 → $15 | $4.34 | +245.62% | 5 | Apr 20, 2026 | |
| DFTX Definium Therapeutics | Maintains: Buy | $25 → $38 | $20.98 | +81.12% | 1 | Apr 16, 2026 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $1.89 | +799.47% | 5 | Apr 14, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $164 → $200 | $128.04 | +56.20% | 18 | Apr 7, 2026 | |
| BIIB Biogen | Maintains: Buy | $230 → $245 | $180.67 | +35.61% | 23 | Apr 1, 2026 | |
| CMPS COMPASS Pathways | Maintains: Buy | $20 → $18 | $8.89 | +102.47% | 6 | Mar 26, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $36 → $60 | $33.71 | +77.99% | 6 | Mar 20, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $35 | $30.64 | +14.23% | 1 | Mar 19, 2026 | |
| CLNN Clene | Maintains: Buy | $48 | $6.06 | +692.08% | 7 | Mar 13, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $19.60 | +99.03% | 5 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $24 | $9.81 | +144.65% | 7 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $27 | $3.82 | +606.81% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.76 | +219.15% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.09 | +7,239.45% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $22.30 | +47.98% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $9.59 | +1,464.13% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $31.26 | - | 2 | Jan 31, 2017 |
AtaiBeckley
Apr 20, 2026
Maintains: Buy
Price Target: $14 → $15
Current: $4.34
Upside: +245.62%
Definium Therapeutics
Apr 16, 2026
Maintains: Buy
Price Target: $25 → $38
Current: $20.98
Upside: +81.12%
Annovis Bio
Apr 14, 2026
Maintains: Buy
Price Target: $17
Current: $1.89
Upside: +799.47%
Neurocrine Biosciences
Apr 7, 2026
Maintains: Buy
Price Target: $164 → $200
Current: $128.04
Upside: +56.20%
Biogen
Apr 1, 2026
Maintains: Buy
Price Target: $230 → $245
Current: $180.67
Upside: +35.61%
COMPASS Pathways
Mar 26, 2026
Maintains: Buy
Price Target: $20 → $18
Current: $8.89
Upside: +102.47%
Stoke Therapeutics
Mar 20, 2026
Maintains: Buy
Price Target: $36 → $60
Current: $33.71
Upside: +77.99%
MapLight Therapeutics
Mar 19, 2026
Initiates: Buy
Price Target: $35
Current: $30.64
Upside: +14.23%
Clene
Mar 13, 2026
Maintains: Buy
Price Target: $48
Current: $6.06
Upside: +692.08%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $19.60
Upside: +99.03%
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $9.81
Upside: +144.65%
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $3.82
Upside: +606.81%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.76
Upside: +219.15%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.09
Upside: +7,239.45%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $22.30
Upside: +47.98%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $9.59
Upside: +1,464.13%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $31.26
Upside: -